Anti-amylase antibody

Antibodies targeting human salivary amylase allow for the detection of saliva on surfaces, addressing the challenge of identifying contamination and preventing disease spread by enabling targeted cleaning and disinfection.

JP2024157233AInactive Publication Date: 2024-11-07KAO CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023071475
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-04-25
Publication Date
2024-11-07
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a need for a method to easily detect the presence of saliva, which may contain infectious disease-causing viruses and bacteria, on surfaces to identify potential contamination and prevent the spread of infection.

Method used

Development of antibodies that bind specifically to human salivary amylase, allowing for the detection of saliva and thereby identifying contaminated objects using a phage display method to obtain highly reactive VHH antibodies.

Benefits of technology

Enables the identification of objects contaminated with infectious agents by detecting human salivary amylase, facilitating effective cleaning and disinfection to prevent the spread of diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024157233000005
    Figure 2024157233000005
  • Figure 2024157233000006
    Figure 2024157233000006
  • Figure 2024157233000001
    Figure 2024157233000001
Patent Text Reader

Abstract

To provide an antibody bound to human salivary amylase and a method for using the same.SOLUTION: The present invention provides an antibody bound to human salivary amylase, with at least one structural domain that includes a CDR composed of a specific amino acid sequence.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an antibody that binds to human salivary amylase and a method for using the same. [Background technology]

[0002] Saliva is a secretion into the oral cavity from three major salivary glands, the parotid gland, the submandibular gland, and the sublingual gland, and several minor salivary glands, and is secreted at a rate of about 1000 to 1500 mL per day in healthy adults. Saliva contains various electrolytes such as sodium, potassium, and calcium, as well as proteins and mucins such as amylase, histatin, and lysozyme, and is known to have functions such as protecting oral tissues, antibacterial activity, and digestion (Non-Patent Document 1).

[0003] Infectious diseases occur when pathogens such as viruses and bacteria invade the body, grow, and cause symptoms such as fever and coughing. The main routes of infection are contact infection via hands or various instruments and parts, droplet infection by directly inhaling droplets generated by coughing, sneezing, or talking, and airborne infection by inhaling droplet nuclei floating in the air. Infectious diseases are established when three factors are present: pathogens (sources of infection), infection routes, and hosts. Therefore, infectious disease control requires the elimination of at least one of these factors, that is, the elimination of pathogens (sources of infection), blocking infection routes, and improving the host's resistance. In particular, blocking infection routes is important for preventing the spread of infection.

[0004] There are two types of contact infection: direct contact infection, in which the pathogen is transmitted directly by touching an infected person, and indirect contact infection, in which the pathogen is transmitted through an object or person contaminated with the pathogen. Here, it is not always easy to determine whether an object is contaminated with a pathogen, and there is a demand for a method that can easily determine whether it is contaminated or not.

[0005] On the other hand, VHH antibodies are natural single-domain antibodies that utilize the variable region of heavy-chain antibodies found in the serum of camelids. Their molecular weight is one-tenth that of IgG antibodies, and they have excellent acid resistance and heat resistance. Furthermore, while IgG antibodies must be produced using cultured cells, VHH antibodies can be produced in E. coli or yeast. In addition, because VHH antibodies are single-chain peptides, their functions can be easily modified by protein engineering or chemical modification, making it easy to create antibody-drug conjugates (ADCs). On the other hand, there is a problem in that it is difficult to obtain VHH antibodies that have high affinity for the substrate. [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] SP Humphrey, RT Williamson, J Prosthet Dent. 2001, 85(2):162-9 Summary of the Invention [Problem to be solved by the invention]

[0007] In many cases, the saliva of an infected person contains the virus and / or bacteria that cause the infectious disease, and objects onto which the scattered saliva adheres may be contaminated with the virus and / or bacteria. Therefore, if saliva can be detected, objects onto which the saliva adheres, i.e., objects that are or may be contaminated with the virus and / or bacteria, can be identified. Human salivary amylase is an enzyme contained in saliva, and locations where high amounts of human salivary amylase are detected are assumed to be locations where amylase or components containing amylase, such as saliva, are likely to adhere in various forms. Thus, the present invention relates to providing an antibody that binds to human salivary amylase and is capable of detecting salivary amylase contained in human saliva, and a method for using the same. [Means for solving the problem]

[0008] The present inventors conducted an investigation to obtain an antibody that binds to human salivary amylase, and as a result, they succeeded in obtaining a clone highly reactive with human salivary amylase by screening a VHH antibody library using a phage display method.

[0009] That is, the present invention relates to the following 1) to 4). 1) An antibody that binds to human salivary amylase, which has one or more structural domains containing CDRs shown in (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) or (k) below. (a) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 1 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 2 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 3 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (b) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 4 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 5 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 6 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (c) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 7 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 8 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 9 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (d) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 10 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 11 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 12 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (e) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 13 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 14 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 15 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (f) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 16 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 17 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 18 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (g) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 19 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 20 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 21 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (h) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 22 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 23 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 24 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (i) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 25 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 26 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 27 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (j) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 28 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 29 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 30 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (k) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 31 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 32 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 33 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. . 2) A nucleic acid encoding the antibody of 1). 3) A method for detecting human salivary amylase in a sample, comprising a step of contacting the antibody of 1) with the test sample. 4) A human salivary amylase detection kit containing the antibody of 1). Effect of the Invention

[0010] According to the present invention, a highly reactive anti-human salivary amylase antibody can be provided. By using the antibody, human saliva can be detected, and objects to which saliva has adhered, i.e., objects that are contaminated or may be contaminated with viruses and / or bacteria that cause infectious diseases, can be identified, and measures to prevent infection or the spread of infectious diseases, such as cleaning and disinfecting the objects, can be effectively taken. [Brief description of the drawings]

[0011] [Figure 1] Electrophoretic images of proteins purified from culture supernatant of Bacillus subtilis incorporating genes encoding VHH antibodies (SEQ ID NOs: 34 to 44). [Diagram 2] Amino acid sequences of the CDR regions obtained by screening using the phage display method. SEQ ID NOs: 34 to 44 show representative sequences, m indicates a mutant, and the gray parts in the mutants indicate amino acid residues that differ from the amino acid sequences of the CDR regions of the representative sequences. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] The antibody of the present invention that binds to human salivary amylase (hereinafter referred to as the "antibody of the present invention") is an anti-human salivary amylase antibody having one or more structural domains including CDR1 to 3 shown in (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) or (k) below. (a) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 1 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 2 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 3 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (b) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 4 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 5 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 6 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (c) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 7 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 8 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 9 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (d) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 10 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 11 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 12 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (e) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 13 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 14 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 15 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (f) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 16 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 17 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 18 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (g) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 19 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 20 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 21 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (h) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 22 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 23 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 24 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (i) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 25 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 26 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 27 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (j) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 28 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 29 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 30 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (k) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 31 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 32 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 33 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids.

[0013] Human salivary amylase refers to an enzyme (α-amylase, EC 3.2.1.1) found in human saliva that catalyzes the hydrolysis of starch and other linear or branched 1,4-glycosidic oligosaccharides or polysaccharides.

[0014] The structural domain of the antibody of the present invention has three CDRs, namely, CDR1, CDR2, and CDR3. A CDR (Complementarity Determining Region) includes a sequence-variable antigen recognition site or a random sequence region, and is also called a hypervariable region. In the structural domain of the antibody of the present invention, the three CDRs are present in the order of CDR1, CDR2, and CDR3 from the N-terminus.

[0015] The amino acid sequences shown in SEQ ID NOs: 1 to 33 are shown in Table 1 below.

[0016] [Table 1]

[0017] The CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 1, 4, 7, 10, 13, 16, 19, 22, 25, 28 or 31 in which 1 to 7 amino acids have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted means a CDR1 in which a mutation has been introduced into the CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 1, 4, 7, 10, 13, 16, 19, 22, 25, 28 or 31. The CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 23, 26, 29 or 32 in which 1 to 6 amino acids have been substituted with other amino acids means a CDR2 in which a mutation has been introduced into the CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 23, 26, 29 or 32. The CDR3 consisting of an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence shown in SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30 or 33 have been substituted with other amino acids means a CDR3 in which a mutation has been introduced into a CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30 or 33. Even if a mutation has been introduced into CDR1, CDR2 or CDR3, it is still encompassed in the CDRs of the antibody of the present invention as long as it has the ability to bind to human salivary amylase.

[0018] In the above (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), or (k), the positions of the amino acids to be substituted and / or deleted or inserted are not limited, but preferred substitution positions include the following positions. (a) In CDR1, preferably 1 to 4 positions, more preferably 1 position, selected from the 2nd, 4th, 5th and 7th positions in the amino acid sequence shown in SEQ ID NO: 1; in CDR2, preferably 1 or 2 positions, more preferably 1 position, selected from the 7th and 8th positions in the amino acid sequence shown in SEQ ID NO: 2; and in CDR3, preferably 1 or 2 positions, more preferably 1 position, selected from the 3rd and 11th positions in the amino acid sequence shown in SEQ ID NO: 3. (b) In CDR1, preferably 1 to 5 positions, more preferably 1 position, selected from the 1st, 2nd, 5th, 6th and 7th positions in the amino acid sequence shown in SEQ ID NO: 4 are included; in CDR2, preferably the 4th position in the amino acid sequence shown in SEQ ID NO: 5 is included; and in CDR3, preferably 1 to 3 positions, more preferably 1 position, selected from the 3rd, 6th and 11th positions in the amino acid sequence shown in SEQ ID NO: 6 are included. (c) In CDR1, preferably 1 to 4 positions, more preferably 1 position, selected from the 1st, 3rd, 4th and 5th positions in the amino acid sequence shown in SEQ ID NO: 7, and in CDR2, preferably 1 to 3 positions, more preferably 1 position, selected from the 3rd, 4th and 8th positions in the amino acid sequence shown in SEQ ID NO: 8, are included. (d) In CDR1, preferably 1 to 7 positions, more preferably 1 position, selected from the 1st, 2nd, 3rd, 4th, 5th, 6th and 7th positions in the amino acid sequence shown in SEQ ID NO: 10; in CDR2, preferably 1 or 2 positions, more preferably 1 position, selected from the 1st and 7th positions in the amino acid sequence shown in SEQ ID NO: 11; and in CDR3, preferably 1 to 3 positions, more preferably 1 position, selected from the 2nd, 3rd, 5th, 6th, 8th, 9th and 10th positions in the amino acid sequence shown in SEQ ID NO: 12. (e) In CDR1, the amino acid sequence includes preferably 1 to 6 positions, more preferably 1 position, selected from the 2nd, 3rd, 4th, 5th, 6th and 7th positions in the amino acid sequence shown in SEQ ID NO:13. (f) In CDR1, preferably 1 to 7 positions, more preferably 1 position, selected from the 1st, 2nd, 3rd, 4th, 5th, 6th and 7th positions in the amino acid sequence shown in SEQ ID NO: 16; in CDR2, preferably 1 to 6 positions, more preferably 1 position, selected from the 1st, 3rd, 4th, 5th, 7th and 8th positions in the amino acid sequence shown in SEQ ID NO: 17; and in CDR3, preferably 1 or 2 positions, more preferably 1 position, selected from the 3rd and 7th positions in the amino acid sequence shown in SEQ ID NO: 18. (g) In CDR1, preferably one or two, more preferably one, positions selected from the 1st and 6th positions of the amino acid sequence shown in SEQ ID NO:19 are exemplified, and in CDR3, preferably the 9th position of the amino acid sequence shown in SEQ ID NO:21 is exemplified. (h) In CDR1, the amino acid sequence includes preferably 1 to 3 positions, more preferably 1 position, selected from the 3rd, 5th and 7th positions in the amino acid sequence shown in SEQ ID NO:22. (i) For CDR1, the first position in the amino acid sequence shown in SEQ ID NO:25 is preferably exemplified, and for CDR2, the fourth position in the amino acid sequence shown in SEQ ID NO:26 is preferably exemplified. (j) In CDR1, preferably 1 to 5, more preferably 1 position selected from the 3rd, 4th, 5th, 6th and 7th positions in the amino acid sequence shown in SEQ ID NO: 28 are included; in CDR2, preferably 1 to 4, more preferably 1 position selected from the 3rd, 4th, 7th and 8th positions in the amino acid sequence shown in SEQ ID NO: 29 are included; and in CDR3, a preferred example is the 8th position in the amino acid sequence shown in SEQ ID NO: 30. (k) In CDR3, the sixth position in the amino acid sequence shown in SEQ ID NO:33 is preferred.

[0019] In addition, the type of amino acid after substitution is not limited, but preferred substitutions include substitution with amino acids of similar polarity or size. In addition, substitution of an isoleucine residue with a leucine residue, a phenylalanine residue, a threonine residue, or a serine residue, substitution of an aspartic acid residue with an alanine residue, a glycine residue, a valine residue, an asparagine residue, or a serine residue, substitution of a serine residue with an arginine residue, an asparagine residue, a threonine residue, a proline residue, an isoleucine residue, a leucine residue, an aspartic acid residue, a phenylalanine residue, a cysteine ​​residue, a tyrosine residue, or a glycine residue, substitution of an asparagine residue with a lysine residue, an isoleucine residue, a serine residue, a threonine residue, or a tyrosine residue, substitution of an arginine residue with a lysine residue, a cysteine ​​residue, a serine residue, a cysteine ​​residue, or a glycine residue, Preferred examples of substitutions include substitution of a threonine residue with a proline residue, an alanine residue, a cysteine ​​residue, a serine residue, an isoleucine residue, a glycine residue or an aspartic acid residue, substitution of a tyrosine residue with an aspartic acid residue, substitution of a histidine residue, a phenylalanine residue, a proline residue or a serine residue, substitution of a tryptophan residue with a serine residue, substitution of a leucine residue with a phenylalanine residue, substitution of an alanine residue with a valine residue, a threonine residue or an aspartic acid residue, substitution of a glycine residue with a glutamic acid residue or an arginine residue, substitution of a phenylalanine residue with a leucine residue or a serine residue, and substitution of a histidine residue with an asparagine residue.

[0020] In the above (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) or (k), preferred combinations of the position of the amino acid to be substituted and the type of the amino acid after substitution include the following combinations. (a) In CDR1, preferably 1 to 4, more preferably 1 substitution selected from the group consisting of substitution of the second isoleucine residue with a leucine residue, substitution of the fourth aspartic acid residue with an alanine residue, substitution of the fifth serine residue with an arginine residue, and substitution of the seventh aspartic acid residue with a glycine residue or an alanine residue in the amino acid sequence shown in SEQ ID NO: 1; in CDR2, preferably 1 or 2, more preferably 1 substitution selected from the group consisting of substitution of the seventh aspartic acid residue with a glycine residue and substitution of the eighth asparagine residue with a lysine residue in the amino acid sequence shown in SEQ ID NO: 2; and in CDR3, preferably 1 or 2, more preferably 1 substitution selected from the group consisting of substitution of the third asparagine residue with an isoleucine residue and substitution of the eleventh arginine residue with a lysine residue in the amino acid sequence shown in SEQ ID NO: 3. (b) In CDR1, preferably 1 to 5, more preferably 1 substitution selected from the group consisting of substitution of the first arginine residue with a cysteine ​​residue, substitution of the second threonine residue with a proline residue, substitution of the fifth serine residue with an asparagine residue, a threonine residue or an arginine residue, substitution of the sixth serine residue with a proline residue, and substitution of the seventh aspartic acid residue with an alanine residue or a glycine residue in the amino acid sequence shown in SEQ ID NO: 4; in CDR2, preferably 1 to 3, more preferably 1 substitution selected from the group consisting of substitution of the third serine residue with an arginine residue, substitution of the sixth serine residue with an isoleucine residue, and substitution of the eleventh tyrosine residue with an aspartic acid residue in the amino acid sequence shown in SEQ ID NO: 6, and in CDR3, preferably 1 to 3, more preferably 1 substitution selected from the group consisting of substitution of the third serine residue with an arginine residue, substitution of the sixth serine residue with an isoleucine residue, and substitution of the eleventh tyrosine residue with an aspartic acid residue in the amino acid sequence shown in SEQ ID NO: 6. (c) In CDR1, preferably 1 to 4 substitutions, more preferably 1 substitution, selected from the group consisting of substitution of the first serine residue with an arginine residue, substitution of the third serine residue with a leucine residue, substitution of the fourth serine residue with an aspartic acid residue, and substitution of the fifth asparagine residue with a serine residue in the amino acid sequence shown in SEQ ID NO: 7; and in CDR2, preferably 1 to 3 substitutions, more preferably 1 substitution, selected from the group consisting of substitution of the third serine residue with a threonine residue, substitution of the fourth tryptophan residue with a serine residue, and substitution of the eighth serine residue with a threonine residue in the amino acid sequence shown in SEQ ID NO: 8. (d) in CDR1, the substitutions include preferably 1 to 7, more preferably 1 substitution selected from the group consisting of substitution of the first arginine residue in the amino acid sequence shown in SEQ ID NO: 10 with a serine residue or a cysteine ​​residue, substitution of the second isoleucine residue with a phenylalanine residue or a leucine residue, substitution of the third leucine residue with a phenylalanine residue, substitution of the fourth aspartic acid residue with an alanine residue, a valine residue or a glycine residue, substitution of the fifth serine residue with a cysteine ​​residue, an arginine residue or an isoleucine residue, substitution of the sixth serine residue with a tyrosine residue, a threonine residue or a phenylalanine residue, and substitution of the seventh alanine residue with a valine residue in the amino acid sequence shown in SEQ ID NO: 11; and in CDR2, the substitution of the first glycine residue in the amino acid sequence shown in SEQ ID NO: 11 with a glutamic acid residue. and substitution of the seventh aspartic acid residue with a valine or asparagine residue; and in CDR3, preferably 1 to 3, more preferably 1 substitution selected from the group consisting of substitution of the second serine residue in the amino acid sequence shown in SEQ ID NO: 12 with a cysteine ​​residue, substitution of the third asparagine residue with a lysine residue or serine residue, substitution of the fifth threonine residue with an alanine residue or cysteine ​​residue, substitution of the sixth tyrosine residue with a histidine residue, phenylalanine residue or aspartic acid residue, substitution of the eighth glycine residue with an arginine residue, substitution of the ninth threonine residue with an alanine residue, serine residue or proline residue, and substitution of the tenth alanine residue with a threonine residue. (e) In CDR1, preferably 1 to 6, more preferably 1 substitution selected from the group consisting of substitution of the second isoleucine residue in the amino acid sequence shown in SEQ ID NO: 13 with a threonine residue, substitution of the third phenylalanine residue with a leucine residue, substitution of the fourth serine residue with an aspartic acid residue or an asparagine residue, substitution of the fifth isoleucine residue with a serine residue, substitution of the sixth serine residue with a tyrosine residue, and substitution of the seventh aspartic acid residue with an alanine residue. (f) In CDR1, the substitutions include preferably 1 to 7, more preferably 1 substitution selected from the group consisting of substitution of the first serine residue in the amino acid sequence shown in SEQ ID NO: 16 with a cysteine ​​residue or an arginine residue, substitution of the second threonine residue with an isoleucine residue, substitution of the third phenylalanine residue with a leucine residue or a serine residue, substitution of the fourth serine residue with an aspartic acid residue, substitution of the fifth asparagine residue with a serine residue or an isoleucine residue, substitution of the sixth serine residue with a tyrosine residue, and substitution of the seventh alanine residue with an aspartic acid residue; and in CDR2, the substitution of the first threonine residue in the amino acid sequence shown in SEQ ID NO: 17 with a glycine residue or an alanine residue residue, substitution of the third serine residue with a threonine residue or an asparagine residue, substitution of the fourth arginine residue with a serine residue or a glycine residue, substitution of the fifth serine residue with a glycine residue, substitution of the seventh threonine residue with an aspartic acid residue or a glycine residue, and substitution of the eighth asparagine residue with a threonine residue or a tyrosine residue. In CDR3, preferably one or two substitutions, more preferably one substitution, selected from the group consisting of substitution of the third histidine residue with an asparagine residue and substitution of the seventh tyrosine residue with a proline residue in the amino acid sequence shown in SEQ ID NO:18. (g) In CDR1, preferably one or two substitutions, more preferably one substitution, selected from the group consisting of substitution of the first arginine residue in the amino acid sequence shown in SEQ ID NO:19 with a cysteine ​​residue and substitution of the sixth serine residue in the amino acid sequence shown in SEQ ID NO:19 with a phenylalanine residue are included. In CDR3, a preferred example is substitution of the ninth threonine residue in the amino acid sequence shown in SEQ ID NO:21 with an alanine residue. (h) In CDR1, preferably 1 to 3 substitutions, more preferably 1 substitution, selected from the group consisting of substitution of the third serine residue in the amino acid sequence shown in SEQ ID NO: 22 with a phenylalanine residue, substitution of the fifth isoleucine residue with a serine residue, and substitution of the seventh aspartic acid residue with an alanine residue, are included. (i) In CDR1, a preferred example is substitution of the first serine residue in the amino acid sequence shown in SEQ ID NO:25 with an arginine residue, and in CDR2, a preferred example is substitution of the fourth serine residue in the amino acid sequence shown in SEQ ID NO:26 with a leucine residue. (j) In CDR1, preferably 1 to 5, more preferably 1 substitution selected from the group consisting of substitution of the serine residue at the 3rd residue with a leucine residue, substitution of the aspartic acid residue at the 4th residue with a serine residue, substitution of the isoleucine residue at the 5th residue with a phenylalanine residue or serine residue, substitution of the tyrosine residue at the 6th residue with a serine residue, and substitution of the alanine residue at the 7th residue with an aspartic acid residue in the amino acid sequence shown in SEQ ID NO: 28; in CDR2, preferably 1 to 4, more preferably 1 substitution selected from the group consisting of substitution of the asparagine residue at the 3rd residue with a serine residue, substitution of the threonine residue at the 4th residue with a serine residue, substitution of the aspartic acid residue at the 7th residue with a glycine residue, and substitution of the asparagine residue at the 8th residue with a tyrosine residue in the amino acid sequence shown in SEQ ID NO: 29; and in CDR3, preferably 1 substitution selected from the group consisting of substitution of the threonine residue at the 8th residue with an alanine residue in the amino acid sequence shown in SEQ ID NO: 30. (k) In CDR3, preferred examples include substitution of the serine residue at position 6 of the amino acid sequence shown in SEQ ID NO: 33 with an arginine residue.

[0021] Tables 2 and 3 below show specific examples of CDR amino acid sequences containing amino acid substitutions in (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) or (k) above, but the substitutions are not limited to these.

[0022] [Table 2]

[0023] [Table 3]

[0024] The binding ability to human salivary amylase can be evaluated by a method known to those skilled in the art. Specifically, as shown in the examples described below, the binding ability can be evaluated by determining the equilibrium dissociation constant KD by biolayer interference method. In addition, the binding ability can also be evaluated by a method using, for example, ELISA method using an antigen immobilized, immunochromatography method, isothermal titration calorimetry method, surface plasmon resonance measurement method, etc.

[0025] The structural domain of the antibody of the present invention may have framework regions on both ends of CDR1, CDR2, and CDR3. The framework region refers to a region in the variable region of an antibody molecule excluding the complementarity determining regions, and is a highly conserved region. That is, one embodiment of the structural domain of the present invention includes a first framework region (FR1), CDR1, second framework region (FR2), CDR2, third framework region (FR3), CDR3 and fourth framework region (FR4) in this order. The amino acid sequences of the framework regions in the structural domains include the following: FR1: the amino acid sequence shown in SEQ ID NO: 67 or an amino acid sequence having 80% or more identity thereto FR2: the amino acid sequence shown in SEQ ID NO: 68 or an amino acid sequence having 80% or more identity thereto FR3: the amino acid sequence shown in SEQ ID NO:69 or an amino acid sequence having 80% or more identity thereto FR4: the amino acid sequence shown in SEQ ID NO: 70 or an amino acid sequence having 80% or more identity thereto

[0026] Examples of framework regions consisting of amino acid sequences having 80% or more identity to the amino acid sequences shown in SEQ ID NOs: 67 to 70 include framework regions consisting of amino acid sequences having preferably 85% or more identity, more preferably 90% or more identity, more preferably 95% or more identity, more preferably 96% or more identity, more preferably 97% or more identity, more preferably 98% or more identity, and more preferably 99% or more identity.

[0027] Here, the identity of amino acid sequences refers to the percentage (%) of the number of positions at which identical amino acid residues exist in two amino acid sequences when the two sequences are aligned relative to the total number of amino acid residues. The identity of sequences can be calculated, for example, by performing an analysis using the Basic Local Alignment Search Tool (BLAST) of the National Center for Biotechnology Information (NCBI).

[0028] Among the antibodies of the present invention, an antibody having a structural domain (SEQ ID NOs: 34 to 44) in which FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 is linked in this order, CDR1, CDR2 and CDR3 are the CDR1, CDR2 and CDR3 shown in Table 1 above, and FR1 has the amino acid sequence shown in SEQ ID NO: 67, FR2 has the amino acid sequence shown in SEQ ID NO: 68, FR3 has the amino acid sequence shown in SEQ ID NO: 69, and FR4 has the amino acid sequence shown in SEQ ID NO: 70, is obtained by screening using a phage display method using human salivary amylase as an antigen, as shown in the examples described below, and is a suitable anti-human salivary amylase antibody that shows good binding affinity to human salivary amylase.

[0029] The amino acid sequences of CDR1, CDR2 and CDR3 shown in Tables 2 and 3, which contain one or more amino acid substitutions in at least one of the amino acid sequences of CDR1, CDR2 and CDR3 shown in Table 1, were extracted by screening using a phage display method with human salivary amylase as an antigen, as shown in the Examples below, and such substitutions maintain binding to human salivary amylase. Therefore, an antibody in which FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 are linked in this order, CDR1, CDR2 and CDR3 are CDR1, CDR2 and CDR3 shown in Tables 2 and 3, and the structural domains are FR1 with the amino acid sequence shown in SEQ ID NO: 67, FR2 with the amino acid sequence shown in SEQ ID NO: 68, FR3 with the amino acid sequence shown in SEQ ID NO: 69 and FR4 with the amino acid sequence shown in SEQ ID NO: 70, is also a suitable anti-human salivary amylase antibody.

[0030] The form of the antibody of the present invention is not limited as long as it has at least one of the above structural domains, and it may be a single domain antibody or a multimer (e.g., a dimer) in which multiple single domain antibodies are bound. Multimers include multimers in which multiple structural domains of the present invention are bound, as well as multimers in which one or more of the structural domains are linked to one or more other structural domains that have antigen specificity different from that of the structural domains. A single domain antibody refers to an antibody that has the property of specifically binding to an antigen through a single variable region (antigen-binding domain). Single domain antibodies include antibodies whose variable region consists only of a heavy chain variable region (heavy chain single domain antibody) and antibodies whose variable region consists only of a light chain variable region (light chain single domain antibody). VHH, which is a heavy chain antibody identified in camelids (e.g., camel, llama, alpaca, etc.), and VNAR, which is a heavy chain antibody derived from cartilaginous fish (e.g., shark), are known as types of single domain antibodies, and in the present invention, VHH antibodies are preferred. In addition, the antibodies of the present invention may be humanized.

[0031] The method for producing the antibody of the present invention is not particularly limited, and the antibody can be easily produced by known techniques in the art. For example, the antibody can be produced by combining solid-phase peptide synthesis and native chemical ligation (NCL) or by genetic engineering, but a preferred method involves incorporating a nucleic acid encoding the antibody of the present invention into an appropriate vector, introducing the vector into a host cell, and producing the antibody as a recombinant antibody.

[0032] Examples of host cells used in the production of recombinant antibodies include Escherichia coli, Bacillus subtilis, mold, animal cells, plant cells, baculovirus / insect cells, and yeast cells. The expression vector for expressing the antibody can be a vector suitable for various host cells. Examples of expression vectors that can be used include vectors derived from Escherichia coli such as pBR322, pBR325, pUC12, and pUC13; vectors derived from Bacillus subtilis such as pUB110, pTP5, and pC194; shuttle vectors that can be used in common between Escherichia coli and Bacillus subtilis such as pHY300PLK; vectors derived from yeast such as pSH19 and pSH15; bacteriophages such as λ phage; viruses such as adenovirus, adeno-associated virus, lentivirus, vaccinia virus, and baculovirus; and vectors modified from these. These expression vectors have a replication origin, a selection marker, and a promoter suitable for each vector, and may have an enhancer, a transcription termination sequence (terminator), a ribosome binding site, a polyadenylation signal, etc. Furthermore, in order to facilitate purification of the expressed polypeptide, the expression vector may have inserted therein a base sequence for expressing a fused tag such as a FLAG tag, a His tag, an HA tag, or a GST tag.

[0033] When extracting the expressed antibody of the present invention from cultured bacteria or cells, after culturing, the bacteria or cultured cells are collected by a known method, suspended in an appropriate buffer, and the bacteria or cells are disrupted by ultrasonication, lysozyme and / or freeze-thawing, etc., and then a soluble extract is obtained by centrifugation or filtration. The target antibody can be obtained from the obtained extract by appropriately combining known separation and purification methods. Known separation and purification methods include methods that utilize solubility, such as salting out and solvent precipitation; methods that utilize mainly differences in molecular weight, such as dialysis, ultrafiltration, gel filtration, and SDS-PAGE; methods that utilize differences in charge, such as ion exchange chromatography; methods that utilize specific affinity, such as affinity chromatography; methods that utilize differences in hydrophobicity, such as reversed-phase high performance liquid chromatography; and methods that utilize differences in isoelectric point, such as isoelectric focusing.

[0034] Since the antibody of the present invention binds to human salivary amylase, by contacting this with a test sample, the presence or absence of human salivary amylase in the sample can be confirmed. Specifically, detection of human salivary amylase using the antibody of the present invention comprises the steps of contacting the antibody of the present invention with a test sample to form a complex between the antibody of the present invention and human salivary amylase in the test sample, and detecting the human salivary amylase in the complex.

[0035] The test sample may include a sample that may contain saliva, a sample collected from an object that may have saliva attached thereto, and preferably a sample collected from the surface of an inanimate object that may have saliva attached thereto. Here, examples of the surface of an inanimate object include hard surfaces such as counters, sinks, restrooms, toilets, bathtubs, showers, floors, windows, doorknobs, walls, sewer outlets, and pipes in homes and business facilities; hard surfaces such as various utensils, tools, and miscellaneous goods such as kitchen utensils, furniture, telephones, and toys; and soft surfaces such as textile products (carpets, area rugs, curtains, fabric furniture, clothing, masks, etc.). The means for collecting such a sample is not particularly limited, but may be, for example, a means for collecting the sample by contacting absorbent cotton, nonwoven fabric, sponge, etc. as a collection part with the surface of the detection object. When the sampling means is used, the sampling part after being brought into contact with the surface of the object to be detected can be brought into contact with an extracting liquid capable of extracting human salivary amylase, for example, by immersing the sampling part in an extracting liquid capable of extracting human salivary amylase contained in a suitable container, and the obtained extracting liquid can be brought into contact with the antibody of the present invention. The antibody may or may not be immobilized on a solid phase. The step of detecting human salivary amylase in the conjugate can be carried out, for example, by reacting the conjugate with another antibody of the present invention or an anti-human salivary amylase antibody that recognizes an epitope different from that of the antibody of the present invention in the conjugate. Alternatively, human salivary amylase in the conjugate may be detected in a liquid phase by a homogeneous assay.

[0036] Furthermore, the antibody of the present invention can be a component of a kit for detecting human saliva amylase. The kit can be used as a tool for identifying an object to which human saliva has adhered, preferably a location in the object to which human saliva has adhered. In many cases, the saliva of an infected person with an infectious disease contains a virus and / or a bacterium that causes the infectious disease. Therefore, if an object to which human saliva has adhered can be identified, it becomes possible to identify an object that is contaminated or may be contaminated with a virus and / or a bacterium, that is, to visualize the risk of infection with an infectious disease, and it becomes possible to effectively take measures to prevent infection or the spread of infection by cleaning and disinfecting the object, etc.

[0037] The detection kit can contain, in addition to the anti-human salivary amylase antibody of the present invention, reagents and instruments necessary for detection, such as an antibody, a solid phase carrier, a buffer solution, an enzyme reaction stopping solution, a microplate reader, and the like. In the detection kit, the antibody of the present invention may be immobilized on a solid phase, such as beads, a membrane, the side or bottom surface of a reaction vessel, a plate-like substrate such as a slide glass, or a well substrate such as an immunoplate, to which the antibody of the present invention is directly or indirectly immobilized.

[0038] In the present invention, the following aspects are further disclosed in relation to the above-mentioned embodiment. <1> An antibody that binds to human salivary amylase, having one or more structural domains containing CDRs shown in (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) or (k) below. (a) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 1 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 2 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 3 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (b) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 4 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 5 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 6 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (c) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 7 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 8 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 9 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (d) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 10 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 11 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 12 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (e) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 13 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 14 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 15 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (f) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 16 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 17 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 18 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (g) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 19 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 20 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 21 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (h) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 22 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 23 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 24 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (i) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 25 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 26 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 27 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (j) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 28 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 29 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 30 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. (k) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 31 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been substituted with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 32 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been substituted with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 33 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been substituted with other amino acids. <2> The amino acid substitution in (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) or (k) is <1> antibodies. (a) the amino acid substitution in the amino acid sequence shown in SEQ ID NO:1 is 1 to 4, preferably 1 substitution selected from the group consisting of substitution of the second isoleucine residue with a leucine residue, substitution of the fourth aspartic acid residue with an alanine residue, substitution of the fifth serine residue with an arginine residue, and substitution of the seventh aspartic acid residue with a glycine residue or an alanine residue; the amino acid substitution in the amino acid sequence shown in SEQ ID NO:2 is 1 or 2, preferably 1 substitution selected from the group consisting of substitution of the seventh aspartic acid residue with a glycine residue and substitution of the eighth asparagine residue with a lysine residue; and the amino acid substitution in the amino acid sequence shown in SEQ ID NO:3 is 1 or 2, preferably 1 substitution selected from the group consisting of substitution of the third asparagine residue with an isoleucine residue and substitution of the eleventh arginine residue with a lysine residue. (b) the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 4 is 1 to 5, preferably 1 substitution selected from the group consisting of substitution of the first arginine residue with a cysteine ​​residue, substitution of the second threonine residue with a proline residue, substitution of the fifth serine residue with an asparagine residue, a threonine residue or an arginine residue, substitution of the sixth serine residue with a proline residue, and substitution of the seventh aspartic acid residue with an alanine residue or a glycine residue; the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 5 is substitution of the fourth serine residue with a proline residue; and the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 6 is 1 to 3, preferably 1 substitution selected from the group consisting of substitution of the third serine residue with an arginine residue, substitution of the sixth serine residue with an isoleucine residue, and substitution of the eleventh tyrosine residue with an aspartic acid residue. (c) the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 7 is 1 to 4, preferably 1, substitutions selected from the group consisting of substitution of the first serine residue with an arginine residue, substitution of the third serine residue with a leucine residue, substitution of the fourth serine residue with an aspartic acid residue, and substitution of the fifth asparagine residue with a serine residue; and the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 8 is 1 to 3, preferably 1, substitution selected from the group consisting of substitution of the third serine residue with a threonine residue, substitution of the fourth tryptophan residue with a serine residue, and substitution of the eighth serine residue with a threonine residue. (d) the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 10 is 1 to 7, preferably 1 substitution selected from the group consisting of substitution of the first arginine residue with a serine residue or a cysteine ​​residue, substitution of the second isoleucine residue with a phenylalanine residue or a leucine residue, substitution of the third leucine residue with a phenylalanine residue, substitution of the fourth aspartic acid residue with an alanine residue, a valine residue or a glycine residue, substitution of the fifth serine residue with a cysteine ​​residue, an arginine residue or a isoleucine residue, substitution of the sixth serine residue with a tyrosine residue, a threonine residue or a phenylalanine residue, and substitution of the seventh alanine residue with a valine residue, and the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 11 is 1 to 7, preferably 1 substitution selected from the group consisting of substitution of the first glycine residue with a glutamine residue and the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 12 is one or two, preferably one substitution selected from the group consisting of substitution of the second serine residue with a cysteine ​​residue, substitution of the third asparagine residue with a lysine residue or serine residue, substitution of the fifth threonine residue with an alanine residue or cysteine ​​residue, substitution of the sixth tyrosine residue with a histidine residue, a phenylalanine residue or an aspartic acid residue, substitution of the eighth glycine residue with an arginine residue, substitution of the ninth threonine residue with an alanine residue, a serine residue or a proline residue, and substitution of the tenth alanine residue with a threonine residue. (e) The amino acid substitution in the amino acid sequence shown in SEQ ID NO: 13 is 1 to 6, preferably 1, substitution selected from the group consisting of substitution of the second isoleucine residue with a threonine residue, substitution of the third phenylalanine residue with a leucine residue, substitution of the fourth serine residue with an aspartic acid residue or an asparagine residue, substitution of the fifth isoleucine residue with a serine residue, substitution of the sixth serine residue with a tyrosine residue, and substitution of the seventh aspartic acid residue with an alanine residue. (f) the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 16 is 1 to 7, preferably 1 substitution selected from the group consisting of substitution of the first serine residue with a cysteine ​​residue or an arginine residue, substitution of the second threonine residue with an isoleucine residue, substitution of the third phenylalanine residue with a leucine residue or a serine residue, substitution of the fourth serine residue with an aspartic acid residue, substitution of the fifth asparagine residue with a serine residue or an isoleucine residue, substitution of the sixth serine residue with a tyrosine residue, and substitution of the seventh alanine residue with an aspartic acid residue, and the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 17 is substitution of the first threonine residue with a glycine residue the substitution of one to six, preferably one, amino acid residues selected from the group consisting of a histidine residue at the third position with an asparagine residue or an alanine residue, a substitution of the third serine residue with a threonine residue or an asparagine residue, a substitution of the fourth arginine residue with a serine residue or a glycine residue, a substitution of the fifth serine residue with a glycine residue, a substitution of the seventh threonine residue with an aspartic acid residue or a glycine residue, and a substitution of the eighth asparagine residue with a threonine residue or a tyrosine residue; and the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 18 is one or two, preferably one, substitutions selected from the group consisting of a histidine residue at the third position with an asparagine residue and a substitution of the tyrosine residue at the seventh position with a proline residue. (g) The amino acid substitution in the amino acid sequence shown in SEQ ID NO: 19 is one or two, preferably one, substitutions selected from the group consisting of substitution of the first arginine residue with a cysteine ​​residue and substitution of the sixth serine residue with a phenylalanine residue, and the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 21 is substitution of the ninth threonine residue with an alanine residue. (h) The amino acid substitution in the amino acid sequence shown in SEQ ID NO: 22 is 1 to 3, preferably 1, substitution selected from the group consisting of substitution of the serine residue at position 3 with a phenylalanine residue, substitution of the isoleucine residue at position 5 with a serine residue, and substitution of the aspartic acid residue at position 7 with an alanine residue. (i) the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 25 is a substitution of the first serine residue with an arginine residue, and the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 26 is a substitution of the fourth serine residue with a leucine residue; (j) the amino acid substitution in the amino acid sequence shown in SEQ ID NO:28 is 1 to 5, preferably 1 substitution selected from the group consisting of substitution of the serine residue at the third residue with a leucine residue, substitution of the aspartic acid residue at the fourth residue with a serine residue, substitution of the isoleucine residue at the fifth residue with a phenylalanine residue or serine residue, substitution of the tyrosine residue at the sixth residue with a serine residue, and substitution of the alanine residue at the seventh residue with an aspartic acid residue; the amino acid substitution in the amino acid sequence shown in SEQ ID NO:29 is 1 to 4, preferably 1 substitution selected from the group consisting of substitution of the asparagine residue at the third residue with a serine residue, substitution of the threonine residue at the fourth residue with a serine residue, substitution of the aspartic acid residue at the seventh residue with a glycine residue, and substitution of the asparagine residue at the eighth residue with a tyrosine residue; and the amino acid substitution in the amino acid sequence shown in SEQ ID NO:30 is substitution of the threonine residue at the eighth residue with an alanine residue. (k) the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 33 is a substitution of the 6th serine residue with an arginine residue; <3> The CDRs designated as (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) or (k) are the following CDRs: <1> antibodies. (a) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 1, 79, 80, 81, 82 or 83, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 2, 84 or 85, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 3, 86 or 87 (b) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 4, 88, 89, 90, 91, 92, 93, 94 or 95, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 5 or 96, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 6, 97, 98 or 99 (c) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 7 or 100, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 8 or 101, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 9 (d) CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 10, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115 or 116, CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 11, 117, 118 or 119, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 12, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131 or 132 (e) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 13, 133, 134, 135, 136 or 137, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 14, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 15 (f) CDR1 consisting of the amino acid sequence represented by SEQ ID NO: 16, 138, 139, 140, 141, 142, 143, 144 or 145, CDR2 consisting of the amino acid sequence represented by SEQ ID NO: 17, 146, 147, 148, 149, 150, 151, 152 or 153, and CDR3 consisting of the amino acid sequence represented by SEQ ID NO: 18 or 154 (g) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 19 or 155, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 20, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 21 or 156 (h) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 22 or 157, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 23, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 24 (i) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 25 or 158, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 26 or 159, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 27 (j) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 28, 160 or 161, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 29 or 162, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 30 or 163 (k) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 31, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 32, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 33 or 164 <4> is a single domain antibody or a single domain antibody multimer; <1> ~ <3> Any of the antibodies. <5> A single domain antibody multimer is a multimer in which multiple structural domains are linked together. <4> antibodies. <6> The single domain antibody multimer is a multimer in which one or more of the structural domains are linked to one or more structural domains having antigen specificity different from that of the structural domain. <4> antibodies. <7> VHH antibody or VHH antibody multimer, <1> ~ <3> Any of the antibodies. <8> The VHH antibody multimer is a multimer in which a plurality of the structural domains are linked together. <7> antibodies. <9> The VHH antibody multimer is a multimer in which one or more of the structural domains are linked to one or more structural domains having antigen specificity different from that of the structural domains. <7> antibodies. <10> The structural domain has, in this order, a first framework region (FR1), a CDR1, a second framework region (FR2), a CDR2, a third framework region (FR3), a CDR3 and a fourth framework region (FR4); <1> ~ <9> Any of the antibodies. <11> FR1 to FR4 are composed of the following amino acid sequences: <10> antibodies. FR1: the amino acid sequence shown in SEQ ID NO: 67 or an amino acid sequence having 80% or more identity thereto FR2: the amino acid sequence shown in SEQ ID NO: 68 or an amino acid sequence having 80% or more identity thereto FR3: the amino acid sequence shown in SEQ ID NO:69 or an amino acid sequence having 80% or more identity thereto FR4: the amino acid sequence shown in SEQ ID NO: 70 or an amino acid sequence having 80% or more identity thereto <12> FR1 to FR4 are composed of the following amino acid sequences: <10> antibodies. FR1: amino acid sequence shown in SEQ ID NO:67 FR2: amino acid sequence shown in SEQ ID NO:68 FR3: amino acid sequence shown in SEQ ID NO:69 FR4: amino acid sequence shown in SEQ ID NO: 70

[0039] <13> <1> ~ <12> A nucleic acid encoding any one of the antibodies. <14> <1> ~ <12> A method for detecting human salivary amylase in a sample, comprising the step of contacting a test sample with any one of the antibodies described above. <15> <1> ~ <12> A human salivary amylase detection kit comprising any one of the antibodies described above. EXAMPLES

[0040] Example 1 Screening of VHHs that bind to human salivary amylase Antigen-binding antibody sequences can be obtained by screening a large-scale library containing a variety of antibody sequences. A representative method for screening a library for antigen-specific antibodies is the phage display method. In this method, phages displaying antibody fragments are produced, and DNA containing antigen-binding antibody fragments can be concentrated by repeatedly binding to the antigen, washing, and reinfecting E. coli. Using human salivary amylase (Sigma-Aldrich, A0521) as an antigen, antibodies consisting of any one of the amino acid sequences of SEQ ID NOs: 34 to 44 were isolated from a VHH antibody library by phage display method as VHH antibodies that bind to human salivary amylase. The amino acid sequences of CDR1 to 3 of the antibodies consisting of the amino acid sequences of SEQ ID NOs: 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44 are shown in SEQ ID NOs: 1 to 3, 4 to 6, 7 to 9, 10 to 12, 13 to 15, 16 to 18, 19 to 21, 22 to 24, 25 to 27, 28 to 30, or 31 to 33, respectively. FR1 to 4 of each VHH antibody are common, and their amino acid sequences are shown in SEQ ID NOs: 67 to 70. The sequences in which a His-tag has been added to the amino acid sequences of SEQ ID NOs: 34 to 44 are shown in SEQ ID NOs: 45 to 55, and the base sequences encoding these amino acid sequences are shown in SEQ ID NOs: 56 to 66, respectively.

[0041] Example 2 Preparation of VHH samples using Bacillus subtilis (1) Construction of plasmid for expression of VHH The plasmid sequence was amplified by PCR using the recombinant plasmid pHY-S237 (JP Patent Publication 2014-158430) prepared based on pHY300PLK as a template, a primer set of 5'-GATCCCCGGGAATTCCTGTTATAAAAAAAGG-3' (SEQ ID NO: 71) and 5'-ATGATGTTAAGAAAGAAAACAAAGCAG-3' (SEQ ID NO: 72) and PrimeSTAR Max DNA polymerase (TaKaRa). The promoter DNA derived from the spoVG gene was amplified by PCR using the Bacillus subtilis 168 strain genome as a template and a primer set of 5'-GAATTCCCGGGGATCTAAGAAAAGTGATTCTGGGAGAG-3' (SEQ ID NO: 73) and 5'-CTTTCTTAACATCATAGTAGTTCACCACCTTTTCCC-3' (SEQ ID NO: 74). The obtained promoter DNA was incorporated into a plasmid sequence using the In-Fusion HD Cloning Kit (Takara) to construct a plasmid for expressing VHH linked to the spoVG promoter.

[0042] (2) Design of plasmid expressing VHH that binds to human salivary amylase The plasmid sequence was amplified by PCR using a primer set of 5'-TTGCAGCTGAACTTCTGCTGCAAGAGCTGCCGGAAATAAA-3' (SEQ ID NO: 75) and 5'-CACCATCATCATTAATCTATTAAACTAGTTATAGGG-3' (SEQ ID NO: 76) and PrimeSTAR Max DNA polymerase (TaKaRa). A DNA fragment consisting of any one of the sequences of SEQ ID NOs: 56 to 66 was inserted into the obtained PCR fragment using an In-Fusion HD Cloning Kit (Takara) to construct a VHH expression plasmid containing each of the VHH genes that bind to human salivary amylase.

[0043] (3) Construction of recombinant Bacillus subtilis Introduction of a plasmid or a PCR product into the Bacillus subtilis Dpr9ΔsigF strain was performed by the protoplast method described below. Dpr9ΔsigF is a strain obtained by deleting all nine extracellular protease genes (epr, wprA, mpr, nprB, bpr, nprE, vpr, aprE and aprX) from the Bacillus subtilis 168 strain according to the method described in JP 2006-174707 A, and further deleting the sigF gene involved in sporulation according to the method described in Japanese Patent No. 4336082. Bacillus subtilis stocked in glycerol was inoculated into 1 mL of LB liquid medium and cultured overnight at 30°C and 210 rpm with shaking. The next day, 10 μL of this culture was inoculated into a new 1 mL of LB liquid medium and cultured at 37°C and 210 rpm with shaking for about 2 hours. This culture solution was collected in a 1.5 mL tube, centrifuged at 12,000 rpm for 5 minutes, and the pellet from which the supernatant was removed was suspended in 500 μL of SMMP containing 4 mg / mL of Lysozyme (manufactured by SIGMA) and incubated at 37 ° C for 1 hour. Next, the mixture was centrifuged at 3,500 rpm for 10 minutes, and the pellet from which the supernatant was removed was suspended in 400 μL of SMMP. 33 μL of this suspension was mixed with various plasmids, and 100 μL of 40% PEG was added and vortexed. 350 μL of SMMP was added to this solution, mixed by inversion, and shaken at 30 ° C and 210 rpm for 1 hour, after which the entire amount was applied to a DM3 agar medium plate and incubated at 30 ° C for 2 to 3 days.

[0044] (4) VHH production The recombinant Bacillus subtilis prepared in (3) was inoculated into 1 mL of LB medium containing 50 ppm tetracycline and shaken at 32°C overnight to prepare a preculture solution. Dpr9ΔsigF was inoculated at 1% into 20 mL of 2×L-mal medium in a pleated Erlenmeyer flask and cultured at 30°C for 72 hours with shaking. At the end of the culture, 1 mL of the culture solution was centrifuged in a microtube at 4°C, 15,000 rpm, and 5 minutes to collect the supernatant. The product was then purified using Ni-NTA agarose beads (Fujifilm Wako Pure Chemical Industries) according to the kit protocol. The collected purified sample was mixed with an equal volume of Laemmli Sample Buffer (BIO-RAD) and then heated at 99℃ for 5 minutes to prepare the sample. Mini-PROTEIN TGX Stain-Free (BIO-RAD) was used for the gel. 5μL of sample was applied to each well and electrophoresed at 210V for 25 minutes. Precision Plus protein Unstained standard (BIO-RAD) was used as the molecular weight marker. Protein bands were detected using a ChemiDoc MP Imaging System (Figure 1). As a result, it was confirmed that all VHHs were highly purified.

[0045] Example 3: Measurement of binding activity by biolayer interferometry The binding activity of VHHs consisting of any one of the amino acid sequences of SEQ ID NO: 34 to 44 immobilized on Ni-NTA (NTA) Biosensors (SARTORIUS) to human salivary amylase was measured using Octet (trademark) R8 Protein Analysis System (SARTORIUS). The measurement order for each run was as follows: 1) Baseline step: Measurement for 60 seconds in PBST, 2) Loading step: Measurement for 300 seconds with 1-10 μg / mL VHH diluted in PBST, 3) Baseline step: Measurement for 90 seconds in PBST, 4) Association step: Measurement for 300 seconds with 0, 2.23, 4.45, 8.9, 17.8, 35.6, and 71.2 nM human salivary amylase (Sigma-Aldrich, A0521) diluted in PBST, and 5) Dissociation step: Measurement for 300 seconds in PBST. Global fitting was performed using Octet™ Analysis Studio software version (12.2.2.26) to calculate the binding activity (Table 4). As a result, it was confirmed that VHH consisting of any of the amino acid sequences of SEQ ID NOs: 34 to 44 binds to human salivary amylase.

[0046] [Table 4]

[0047] Example 4 Extraction of CDR region amino acid sequences of DNA obtained by phage display method Plasmids were extracted from the colony population obtained by the phage display method described in Example 1 using NucleoSpin (registered trademark) Plasmid EasyPure (Takara). The resulting plasmid population was used as a template, and the VHH region was amplified by PCR using a primer set of 5'-TAACCATGAAATACCTATTGCC-3' (SEQ ID NO: 77) and 5'-CGCTGCTAACGGTAACCTGG-3' (SEQ ID NO: 78) and PrimeSTAR Max DNA polymerase (TaKaRa), and a sequence library was prepared using NEBNext Ultra II DNA Library Prep Kit for Illumina (NEB). The resulting PCR product was quantified using GenNext (registered trademark) NGS Library Quantification Kit (TOYOBO), diluted to 4 nM, and then sequenced using MiSeq (Illumina) and MiSeq Reagent Nano Kit v2 (500-cycles) (Illumina). The base sequence region encoding VHH was extracted from the sequence data and translated into an amino acid sequence. Mutant sequences with amino acid sequences similar to those of SEQ ID NOs: 34 to 44 were then extracted and the CDR regions were compared (Figure 2). Since the phage display method is a method for enriching VHH sequences that bind to antigens, multiple substitutions that maintain binding to human salivary amylase were identified in VHHs consisting of any of the amino acid sequences of SEQ ID NOs: 34 to 44. The amino acid sequences of the CDRs including the substitutions in Figure 2 are shown in SEQ ID NOs: 79 to 164.

Claims

1. An antibody that binds to human salivary amylase, having one or more structural domains including CDRs shown in (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) or (k) below. (a) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 1 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been replaced with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 2 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been replaced with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 3 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been replaced with other amino acids. (b) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 4 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been replaced with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 5 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been replaced with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 6 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been replaced with other amino acids. (c) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 7 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been replaced with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 8 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been replaced with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 9 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been replaced with other amino acids. (d) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 10 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been replaced with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 11 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been replaced with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 12 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been replaced with other amino acids. (e) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 13 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been replaced with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 14 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been replaced with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 15 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been replaced with other amino acids. (f) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 16 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been replaced with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 17 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been replaced with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 18 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been replaced with other amino acids. (g) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 19 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been replaced with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 20 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been replaced with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 21 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been replaced with other amino acids. (h) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 22 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been replaced with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 23 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been replaced with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 24 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been replaced with other amino acids. (i) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 25 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been replaced with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 26 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been replaced with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 27 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been replaced with other amino acids. (j) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 28 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been replaced with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 29 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been replaced with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 30 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been replaced with other amino acids. (k) CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 31 or an amino acid sequence in which 1 to 7 amino acids in the amino acid sequence have been replaced with other amino acids and / or 1 to 3 amino acids have been deleted or inserted, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 32 or an amino acid sequence in which 1 to 6 amino acids in the amino acid sequence have been replaced with other amino acids, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 33 or an amino acid sequence in which 1 to 3 amino acids in the amino acid sequence have been replaced with other amino acids.

2. The antibody of claim 1, wherein the amino acid substitutions at (a), (b), (c), (d), (e), (f), (g), (h), (i), (j) or (k) are as follows: (a) the amino acid substitutions in the amino acid sequence shown in SEQ ID NO:1 are 1 to 4 substitutions selected from the group consisting of substitution of the second isoleucine residue with a leucine residue, substitution of the fourth aspartic acid residue with an alanine residue, substitution of the fifth serine residue with an arginine residue, and substitution of the seventh aspartic acid residue with a glycine residue or an alanine residue; the amino acid substitutions in the amino acid sequence shown in SEQ ID NO:2 are 1 or 2 substitutions selected from the group consisting of substitution of the seventh aspartic acid residue with a glycine residue and substitution of the eighth asparagine residue with a lysine residue; and the amino acid substitutions in the amino acid sequence shown in SEQ ID NO:3 are 1 or 2 substitutions selected from the group consisting of substitution of the third asparagine residue with an isoleucine residue and substitution of the eleventh arginine residue with a lysine residue. (b) the amino acid substitutions in the amino acid sequence shown in SEQ ID NO: 4 are 1 to 5 substitutions selected from the group consisting of substitution of the first arginine residue with a cysteine ​​residue, substitution of the second threonine residue with a proline residue, substitution of the fifth serine residue with an asparagine residue, a threonine residue or an arginine residue, substitution of the sixth serine residue with a proline residue, and substitution of the seventh aspartic acid residue with an alanine residue or a glycine residue; the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 5 is substitution of the fourth serine residue with a proline residue; and the amino acid substitutions in the amino acid sequence shown in SEQ ID NO: 6 are 1 to 3 substitutions selected from the group consisting of substitution of the third serine residue with an arginine residue, substitution of the sixth serine residue with an isoleucine residue, and substitution of the eleventh tyrosine residue with an aspartic acid residue. (c) the amino acid substitutions in the amino acid sequence shown in SEQ ID NO: 7 are 1 to 4 substitutions selected from the group consisting of substitution of the first serine residue with an arginine residue, substitution of the third serine residue with a leucine residue, substitution of the fourth serine residue with an aspartic acid residue, and substitution of the fifth asparagine residue with a serine residue, and the amino acid substitutions in the amino acid sequence shown in SEQ ID NO: 8 are 1 to 3 substitutions selected from the group consisting of substitution of the third serine residue with a threonine residue, substitution of the fourth tryptophan residue with a serine residue, and substitution of the eighth serine residue with a threonine residue. (d) the amino acid substitutions in the amino acid sequence shown in SEQ ID NO: 10 are 1 to 7 substitutions selected from the group consisting of substitution of the first arginine residue with a serine residue or a cysteine ​​residue, substitution of the second isoleucine residue with a phenylalanine residue or a leucine residue, substitution of the third leucine residue with a phenylalanine residue, substitution of the fourth aspartic acid residue with an alanine residue, a valine residue or a glycine residue, substitution of the fifth serine residue with a cysteine ​​residue, an arginine residue or a isoleucine residue, substitution of the sixth serine residue with a tyrosine residue, a threonine residue or a phenylalanine residue, and substitution of the seventh alanine residue with a valine residue; and the amino acid substitutions in the amino acid sequence shown in SEQ ID NO: 11 are 1 to 7 substitutions selected from the group consisting of substitution of the first glycine residue with a glycine residue, and the amino acid substitutions in the amino acid sequence shown in SEQ ID NO:12 are one to three substitutions selected from the group consisting of substitution of the second serine residue with a cysteine ​​residue, substitution of the third asparagine residue with a lysine residue or serine residue, substitution of the fifth threonine residue with an alanine residue or cysteine ​​residue, substitution of the sixth tyrosine residue with a histidine residue, a phenylalanine residue or an aspartic acid residue, substitution of the eighth glycine residue with an arginine residue, substitution of the ninth threonine residue with an alanine residue, a serine residue or a proline residue, and substitution of the tenth alanine residue with a threonine residue. (e) the amino acid substitutions in the amino acid sequence shown in SEQ ID NO: 13 are 1 to 6 substitutions selected from the group consisting of substitution of the second isoleucine residue with a threonine residue, substitution of the third phenylalanine residue with a leucine residue, substitution of the fourth serine residue with an aspartic acid residue or an asparagine residue, substitution of the fifth isoleucine residue with a serine residue, substitution of the sixth serine residue with a tyrosine residue, and substitution of the seventh aspartic acid residue with an alanine residue; (f) the amino acid substitutions in the amino acid sequence shown in SEQ ID NO:16 are 1 to 7 substitutions selected from the group consisting of substitution of the first serine residue with a cysteine ​​residue or an arginine residue, substitution of the second threonine residue with an isoleucine residue, substitution of the third phenylalanine residue with a leucine residue or a serine residue, substitution of the fourth serine residue with an aspartic acid residue, substitution of the fifth asparagine residue with a serine residue or an isoleucine residue, substitution of the sixth serine residue with a tyrosine residue, and substitution of the seventh alanine residue with an aspartic acid residue, and the amino acid substitutions in the amino acid sequence shown in SEQ ID NO:17 are 1 to 7 substitutions selected from the group consisting of substitution of the first threonine residue with a guanine residue or an arginine residue, substitution of the second threonine residue with an isoleucine residue, substitution of the third phenylalanine residue with a leucine residue or a serine residue, substitution of the fourth serine residue with an aspartic acid residue, substitution of the fifth asparagine residue with a serine residue or an isoleucine residue, substitution of the sixth serine residue with a tyrosine residue, and substitution of the seventh alanine residue with an aspartic acid residue; the substitutions being 1 to 6 selected from the group consisting of a lysine residue or an alanine residue, the substitution of the third serine residue with a threonine residue or an asparagine residue, the substitution of the fourth arginine residue with a serine residue or a glycine residue, the substitution of the fifth serine residue with a glycine residue, the substitution of the seventh threonine residue with an aspartic acid residue or a glycine residue, and the substitution of the eighth asparagine residue with a threonine residue or a tyrosine residue; and the amino acid substitutions in the amino acid sequence shown in SEQ ID NO:18 are 1 or 2 substitutions selected from the group consisting of a substitution of the third histidine residue with an asparagine residue and a substitution of the seventh tyrosine residue with a proline residue. (g) the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 19 is one or two substitutions selected from the group consisting of substitution of the first arginine residue with a cysteine ​​residue and substitution of the sixth serine residue with a phenylalanine residue, and the amino acid substitution in the amino acid sequence shown in SEQ ID NO: 21 is substitution of the ninth threonine residue with an alanine residue; (h) the amino acid substitutions in the amino acid sequence shown in SEQ ID NO:22 are 1 to 3 substitutions selected from the group consisting of substitution of the third serine residue with a phenylalanine residue, substitution of the fifth isoleucine residue with a serine residue, and substitution of the seventh aspartic acid residue with an alanine residue; (i) The amino acid substitution in the amino acid sequence shown in SEQ ID NO:25 is a substitution of the first serine residue with an arginine residue, and the amino acid substitution in the amino acid sequence shown in SEQ ID NO:26 is a substitution of the fourth serine residue with a leucine residue. (j) the amino acid substitutions in the amino acid sequence shown in SEQ ID NO:28 are 1 to 5 substitutions selected from the group consisting of substitution of the third serine residue with a leucine residue, substitution of the fourth aspartic acid residue with a serine residue, substitution of the fifth isoleucine residue with a phenylalanine residue or serine residue, substitution of the sixth tyrosine residue with a serine residue, and substitution of the seventh alanine residue with an aspartic acid residue; the amino acid substitutions in the amino acid sequence shown in SEQ ID NO:29 are 1 to 4 substitutions selected from the group consisting of substitution of the third asparagine residue with a serine residue, substitution of the fourth threonine residue with a serine residue, substitution of the seventh aspartic acid residue with a glycine residue, and substitution of the eighth asparagine residue with a tyrosine residue; and the amino acid substitution in the amino acid sequence shown in SEQ ID NO:30 is substitution of the eighth threonine residue with an alanine residue. (k) the amino acid substitution in the amino acid sequence represented by SEQ ID NO: 33 is a substitution of the 6th serine residue with an arginine residue;

3. 3. The antibody of claim 1 or 2, which is a single domain antibody or a single domain antibody multimer.

4. The antibody according to claim 1 or 2, which is a VHH antibody or a VHH antibody multimer.

5. A nucleic acid encoding the antibody according to any one of claims 1 to 4.

6. A method for detecting human salivary amylase in a test sample, comprising the step of contacting the antibody according to any one of claims 1 to 4 with the test sample.

7. A human salivary amylase detection kit comprising the antibody according to any one of claims 1 to 4.